Second US patent granted
Montreal / April 05, 2024 – NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US ...
05 April, 2024 No comment
Latest Posts Small Image
-
-
Safety clinical trials with NexPlasmaGen’s technology start!
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen med...
08 March, 2025 No comment -
NexPlasmaGen’s to present at the Seed showcase 2022
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022 NexPlasmaGen will pitch its business opportunity to investors! Montreal/De...
24 December, 2021 No comment -
NexPlasmaGen’s CPJ breast cancer in vivo preclinical trials completed
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller d...
03 November, 2021 No comment
-
02 Feb 2023 NexPlasmaGen to present to the OBIO Investment Summit
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/Fe...
02 February, 2023 No comment -
Best MedTech Oncology Business 2024 – Canada
Montreal / April 19, 2024 – NexPlasmaGen is honored to announce that it has won GHP magazine’s Best MedTech ...
19 April, 2024 No comment -
Clinical trials protocol published in BMC Cancer journal
Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in ...
25 April, 2025 No comment -
NexPlasmaGen completed an investment phase to accelerate the development of its cold plasma technology for breast cancer treatment
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, A...
01 July, 2018 No comment